Valeant Pharmaceuticals (VRX): Bill Ackman’s Pershing Square Lands Board Seat

Page 2 of 7 SEC Filing


13D

CUSIP No. 91911K102 Page 2
  1

Name of
reporting person

Pershing Square Capital Management, L.P.

  2

Check the appropriate box if a member
of a group

(a)  ¨        (b)  ¨

  3

SEC use only

  4

Source of funds

OO (See Item 3)

  5

Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)

¨

  6

Citizenship or place of
organization

Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

  7

Sole voting power

0

  8

Shared voting power

30,711,122

  9

Sole dispositive power

0

10

Shared dispositive power

30,711,122

11

Aggregate amount beneficially owned by each reporting person

30,711,122

12

Check box if the aggregate amount in
Row (11) excludes certain shares

¨

13

Percent of class represented by amount
in Row (11)

9.0%(1)

14

Type of reporting person

IA

(1) Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s
quarterly report filed on Form 10-Q on October 26, 2015.

Follow Bausch Health Companies Inc. (NYSE:BHC)